- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion, Trial completion date, Combination therapy, Metastases: A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment (clinicaltrials.gov) - Feb 27, 2019 P1b/2, N=173, Completed, Recruiting --> Completed | N=10 --> 4 Active, not recruiting --> Completed | Trial completion date: May 2017 --> Feb 2018
- |||||||||| Avastin (bevacizumab) / Roche
Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Metastases: Sequential Therapy in Metastatic Renal Cell Carinoma (clinicaltrials.gov) - Feb 6, 2019 P2, N=22, Completed, Active, not recruiting --> Completed | Trial completion date: Dec 2015 --> Dec 2018 Active, not recruiting --> Completed | N=100 --> 22 | Trial completion date: May 2016 --> Sep 2016 | Trial primary completion date: May 2016 --> Sep 2016
- |||||||||| Trial completion, Trial completion date, Trial primary completion date: Urine Proteome of Surgical Patients and Healthy Volunteers (clinicaltrials.gov) - Jan 7, 2019
P=N/A, N=664, Completed, Active, not recruiting --> Completed | N=100 --> 22 | Trial completion date: May 2016 --> Sep 2016 | Trial primary completion date: May 2016 --> Sep 2016 Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Jul 2016 | Trial primary completion date: Dec 2018 --> Jul 2016
- |||||||||| veliparib (ABT-888) / AbbVie
Trial termination, Combination therapy, BRCA Biomarker, PARP Biomarker, Metastases: Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jan 3, 2019 P1, N=44, Terminated, Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Jul 2016 | Trial primary completion date: Dec 2018 --> Jul 2016 Recruiting --> Terminated
- |||||||||| cisplatin / Generic mfg., gemcitabine / Generic mfg., sorafenib / Generic mfg.
Trial completion, Trial completion date, Metastases: Sorafenib Combined With Chemotherapy for Renal Collecting Duct Carcinoma (clinicaltrials.gov) - Nov 20, 2018 P2, N=26, Completed, Trial completion date: May 2016 --> Dec 2018 Active, not recruiting --> Completed | Trial completion date: Jun 2017 --> Jun 2018
- |||||||||| MGN1601 / Mologen
Trial completion, Epigenetic controller, Immunomodulating, Tumor cell, Metastases: A Clinical Study to Assess Safety and Efficacy of a Tumor Vaccine in Patients With Advanced Renal Cell Carcinoma (ASET) (clinicaltrials.gov) - Nov 15, 2018 P1/2, N=19, Completed, Active, not recruiting --> Completed | Trial completion date: Jun 2017 --> Jun 2018 Active, not recruiting --> Completed
- |||||||||| Sutent (sunitinib) / Pfizer
Trial completion, Combination therapy, Metastases: Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT) (clinicaltrials.gov) - Oct 26, 2018 P2, N=63, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Sutent (sunitinib) / Pfizer
Trial completion, Enrollment change, Trial primary completion date: Cardiovascular Effects of Sunitinib Therapy (CREST) (clinicaltrials.gov) - Oct 2, 2018 P=N/A, N=98, Completed, Active, not recruiting --> Completed Recruiting --> Completed | N=20 --> 98 | Trial primary completion date: Apr 2017 --> Dec 2017
- |||||||||| davamotecan pegadexamer (EP0057) / Ellipses Pharma, Avastin (bevacizumab) / Roche
Trial completion, Trial primary completion date, Combination therapy, Metastases: CRLX101 Plus Bevacizumab in Advanced RCC (clinicaltrials.gov) - Aug 29, 2018 P1b, N=22, Completed, Trial primary completion date: Jul 2020 --> Apr 2016 Active, not recruiting --> Completed | Trial primary completion date: Jun 2014 --> Jul 2017
- |||||||||| rocapuldencel-T (CMN-001) / CoImmune, SCM Lifescience
Trial completion date, Trial termination, Trial primary completion date: A Rollover Protocol for Subjects Previously Treated With AGS-003 (clinicaltrials.gov) - Jun 27, 2018 P2, N=2, Terminated, N=88 --> 59 Trial completion date: Dec 2017 --> May 2018 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2017 --> May 2018; Lack of efficacy
- |||||||||| Trial completion, Trial completion date, Trial primary completion date: Vaccine Therapy in Treating Patients With Kidney Cancer (clinicaltrials.gov) - Apr 25, 2018
P1, N=15, Completed, N=40 --> 18 Active, not recruiting --> Completed | Trial completion date: Nov 2019 --> Apr 2018 | Trial primary completion date: Nov 2019 --> Apr 2018
- |||||||||| famitinib (SHR 1020) / Jiangsu Hengrui Pharma
Trial termination, Metastases: A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer (clinicaltrials.gov) - Apr 18, 2018 P2, N=150, Terminated, Active, not recruiting --> Completed | Trial completion date: Nov 2019 --> Apr 2018 | Trial primary completion date: Nov 2019 --> Apr 2018 Active, not recruiting --> Terminated
- |||||||||| Votrient (pazopanib) / Novartis, BeiGene
Trial completion: Study To Assess Long Term Safety Of Pazopanib (clinicaltrials.gov) - Apr 12, 2018 P1, N=188, Completed, Active, not recruiting --> Terminated Active, not recruiting --> Completed
- |||||||||| Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
Biomarker, Trial completion, Phase classification, Metastases: Biomarkers That Predict Response to High-Dose Aldesleukin in Metastatic Kidney Cancer or Metastatic Melanoma (clinicaltrials.gov) - Apr 2, 2018 P, N=15, Completed, N=31 --> 60 Active, not recruiting --> Completed | Phase classification: PN/A --> P
- |||||||||| buparlisib (AN2025) / Novartis, Adlai Nortye
Trial completion, Trial completion date, Trial primary completion date, Metastases: A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies (clinicaltrials.gov) - Mar 19, 2018 P1, N=43, Completed, Recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: May 2018 --> May 2017 | Trial primary completion date: Mar 2018 --> May 2017
- |||||||||| sirolimus / Generic mfg.
Trial completion date, Trial primary completion date, Metastases: A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Mar 8, 2018 P1, N=64, Active, not recruiting, Active, not recruiting --> Completed | Trial completion date: May 2018 --> May 2017 | Trial primary completion date: Mar 2018 --> May 2017 Trial completion date: Jul 2018 --> Jul 2019 | Trial primary completion date: Jul 2018 --> Nov 2016
- |||||||||| Sutent (sunitinib) / Pfizer
Trial completion, Trial completion date, Trial primary completion date, Metastases: Study of Efficacy and Safety of Sunitinib Given on an Individualized Schedule (clinicaltrials.gov) - Mar 6, 2018 P2, N=117, Completed, Trial completion date: Jul 2018 --> Jul 2019 | Trial primary completion date: Jul 2018 --> Nov 2016 Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Sep 2017 | Trial primary completion date: Dec 2017 --> Sep 2017
- |||||||||| Trial completion date, Trial primary completion date: Vaccine Therapy in Treating Patients With Kidney Cancer (clinicaltrials.gov) - Feb 27, 2018
P1, N=15, Active, not recruiting, Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Sep 2017 | Trial primary completion date: Dec 2017 --> Sep 2017 Trial primary completion date: Nov 2018 --> Nov 2019 | Trial completion date: Nov 2018 --> Nov 2019
- |||||||||| Trial completion, Trial completion date, Trial initiation date, Trial primary completion date: Mannitol Use During Partial Nephrectomy Prior to Renal Ischemia and Impact on Renal Function Outcomes (clinicaltrials.gov) - Feb 22, 2018
P3, N=210, Completed, Trial primary completion date: Nov 2018 --> Nov 2019 | Trial completion date: Nov 2018 --> Nov 2019 Active, not recruiting --> Completed | Trial completion date: May 2018 --> Feb 2018 | Initiation date: May 2012 --> May 2012 | Trial primary completion date: May 2018 --> Feb 2018
- |||||||||| Trial completion, Enrollment change, Trial primary completion date: Perfusion Scanning's for Kidney Tumors (clinicaltrials.gov) - Jan 24, 2018
P=N/A, N=56, Completed, N=99 --> 15 Recruiting --> Completed | N=100 --> 56 | Trial primary completion date: Dec 2018 --> Jan 2018
- |||||||||| vatalanib (PTK787) / Novartis, Bayer
Trial completion, Trial primary completion date, Combination therapy, Metastases: Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jan 17, 2018 P1, N=96, Completed, N=20 --> 14 | Active, not recruiting --> Terminated; The sponsor's clinical program for the agent used in this study was discontinued. Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Sep 2009
- |||||||||| Votrient (pazopanib) / Novartis, BeiGene
Trial primary completion date: Study To Assess Long Term Safety Of Pazopanib (clinicaltrials.gov) - Jan 8, 2018 P1, N=195, Active, not recruiting, N=12 --> 5 Trial primary completion date: Dec 2017 --> Mar 2018
|